The French firm said 130 employees would be made redundant at the biomanufacturing site.
Spokesperson Ashleigh Koss told us a plan to transform operations at the Sanofi’s biomanufacturing facilities drove the decision.
“This change is associated with the outsourcing of certain aspects of the production process and various improvements to technology and operations that have been implemented,” she said.
By reducing headcount, the company plans to align staffing levels with the current level of activity on site.
Sanofi said it will continue to invest in operations in Massachusetts, which “remains a critical global hub for Sanofi for manufacturing, R&D and commercial operations.”
“As we continue to invest in expanding our capabilities to bring new therapies to market, we must be flexible in our operations to remain competitive in a dynamic and challenging healthcare environment,” said the firm.
Severance benefits and outplacement assistance will be offered to employees impacted by restructure.
Manufacturing concerns at the Allston facility – under the ownership of biotech Genzyme – resulted in a $175m fine from the US Food and Drug Administration (FDA) in 2010.
Sanofi acquired Genzyme in 2011 for $20.1bn.
Last month, Sanofi told Biopharma-Reporter it will expand its biomanufacturing facility in Framingham, Massachusetts by 14,820 sq. ft. to support its portfolio and pipeline therapies.